-50%

est. 2Y upside i

HealthcareSeries B

Generative AI for Oncology EHRs

Rank

#3686

Sector

Healthcare AI

Est. Liquidity

~4Y

Data Quality

Data: Low

Given the low growth and high preference overhang, the expected equity value is negative over 2 years.

Last updated: July 3, 2026

Bull (10%)+38%

OncoLLM differentiation and marquee customer wins drive multiple expansion to 8x forward revenue, enabled by IPO window or category leadership. Exit value $96.8M.

Base (35%)+4%

Moderate growth persists; multiple converges to comp average of 6x. Exit value $72.6M, representing modest upside.

Bear (55%)-100%

Incumbent competition and slow growth compress multiple to 4x; exit value $48.4M below total funding of $50.9M, resulting in full loss of common equity.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

73%

Total funding of $50.9M represents 73% of estimated $70M valuation, giving preferred a large liquidation preference.

Dilution Risk

low

Recent Series B likely provides 2+ years runway, making near-term dilution unlikely.

Secondary Liquidity

none

No secondary market exists; employees likely must wait for IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Triomics's data — designed to show you've done your homework.

  • 1

    “How does Triomics plan to accelerate growth beyond 9% YoY?”

  • 2

    “What is the path to profitability given the high regulatory and development costs?”

  • 3

    “How does the equity package compare to joining a more mature public company?”

Community

Valuation Sentiment

Our model estimates -50% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.